Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q2 2024 Earnings Call Transcript
Operator: Good afternoon. And welcome to the Trevi Therapeutics Second Quarter 2024 Earnings Conference Call. At this time, all participants will be in a listen-only mode.
Trevi Therapeutics Inc. (TRVI)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Rubric Capital Management David Rosen | 5,026,931 | $14,980,254 | -10% | 0.39% |
| 2. | Viking Global Andreas Halvorsen | 4,400,000 | $13,112,000 | 0.05% | |
| 3. | Logos Capital Arsani William | 2,800,000 | $8,344,000 | +28% | 0.67% |
| 4. | Opaleye Management James A. Silverman | 2,645,000 | $7,882,100 | 1.8% | |
| 5. | BioImpact Capital Mpm Capital | 1,510,174 | $4,500,319 | +13% | 0.69% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.90 | 948,948 | Large Shareholder | 948,948 | 2022-04-11 | Filing | |
| $1.90 | 2,631,578 | Large Shareholder | 10,421,428 | 2022-04-11 | Filing | |
| $1.90 | 948,948 | Large Shareholder | 948,948 | 2022-04-11 | Filing | |
| $1.90 | 2,631,578 | Large Shareholder | 10,421,428 | 2022-04-11 | Filing | |
| $1.90 | 948,948 | Large Shareholder | 948,948 | 2022-04-11 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $3.04 | 1,840 | 213,313 | 2024-09-09 | Filing | ||
| $3.03 | 4,219 | 213,313 | 2024-09-06 | Filing | ||
| $3.11 | 40,277 | 213,313 | 2024-09-05 | Filing | ||
| $3.02 | 10,981 | 213,313 | 2024-09-04 | Filing | ||
| $3.02 | 3,863 | 213,313 | 2024-09-03 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 11,370,376 | $15,236,304 | 1.01% | |
| 2. | 7,381,090 | $9,890,661 | 0.52% | |
| 3. | 3,422,397 | $4,586,012 | 0.31% | |
| 4. | 2,319,716 | $3,108,419 | 0% | |
| 5. | 2,243,399 | $3,006,154 | 0% |
News See All
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q1 2024 Earnings Call Transcript
Operator: Good afternoon, and welcome to the Trevi Therapeutics First Quarter 2024 Earnings Conference Call. At this time, all participants will be in a listen-only mode.
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q4 2023 Earnings Call Transcript
Trevi Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.08, expectations were $-0.1.
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q3 2023 Earnings Call Transcript
Operator: Good afternoon and welcome to the Trevi Therapeutics Q3 2023 Earnings Conference Call. At this time all participants will be in a listen-only mode.
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q2 2023 Earnings Call Transcript
Operator: Good afternoon and welcome to the Trevi Therapeutics’ Second Quarter 2023 Earnings Conference Call. [Operator Instructions] Please note this event is being recorded.
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q1 2023 Earnings Call Transcript
Operator: Good afternoon and welcome to the Trevi Therapeutics’ Q1 2023 Earnings Conference Call. [Operator Instructions] Please note this event is being recorded.
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q4 2022 Earnings Call Transcript
Operator: Good afternoon and welcome to the Trevi Therapeutics Q4 and Year-End 2022 Earnings Conference Call. Please note this event is being recorded.
Billionaire Hedge Funds
